ERAP2 and cancer: While pan-cancer risk analysis implicated individual eQTLs for CTSS, ERAP1, ERAP2, CTSW and class I and II MHC genes (Supplementary Data 11), PRS analysis pointed to additional eQTLs with some shared between melanoma and prostate (FPR1, LYZ, FCGR3B, HLA-G, HLA-H, HLA-DQA1, and HLADQB1), unique to melanoma (MNDA, IL2RA, OAS1, and TAP2) or unique to prostate (AMP3D, SIGLEC5, HLA-B, HLA-C, and HLA-DRB1).